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Background. Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from 
the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population.
Methods. We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually 
transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to 
detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-re-
ported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by a logistic mixed model.
Results. We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled 
VE against HPV-16/18 was 89.9% (81.7%–94.4%). Moreover, we calculated significant VE against nonvaccine types HPV-45 (91%), 
HPV-35 (57%), HPV-31 (50%), and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated sim-
ilar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination <5 years ago (83% 
and 33%, respectively).
Conclusion. We demonstrated high VE of the bivalent vaccine against HPV-16/18 and cross-protection against HPV-
45/35/31/52. Protection against HPV-16/18 was sustained up to 6 years postvaccination.
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Human papillomavirus (HPV) is a sexually transmitted virus 
that is considered a necessary factor in the development of cer-
vical cancer [1]. Many different HPV types have been identi-
fied and classified as high-risk HPV (hrHPV) or low-risk HPV 
based on their oncogenic potential [2]. HrHPV types 16 and 
18 are associated with approximately 71% of all cervical cancer 
cases. Other hrHPV types frequently identified in cervical can-
cers (together in approximately 21% of the cancers) are 31, 33, 
35, 45, 52, and 58 [3]. Prevention of infection with HPV-16/18 
and other hrHPV by means of prophylactic vaccination pro-
vides a tremendous opportunity to prevent cancer [4].
To date, 3 vaccines have been licensed for the prevention of 
HPV-related cancer, providing direct protection against 2, 4, 
or 9 HPV types. The National Immunization Program of the 
Netherlands uses the bivalent vaccine Cervarix®, which was 
licensed in 2007 and targets HPV types 16 and 18 [5]. The Dutch 
HPV vaccination program started in 2009 with a catch-up cam-
paign for girls born in 1993–1996 (12 to 16  years old). From 
2010 onwards, girls are offered vaccination in the year they turn 
13, starting with birth cohort 1997 [6].
The bivalent vaccine trials invariably showed high efficacy 
against persistent HPV-16/18 infection and associated pre-
cancer lesions of over 90% [7]. Moreover, some level of cross- 
protection against nonvaccine hrHPV types was shown in the 
vaccine trials, but results are less conclusive and dependent on 
the population and outcome studied [7–10].
Observational studies after the implementation of large-scale 
immunization programs are important to assess the vaccine 
effectiveness (VE) against both the vaccine and nonvaccine 
types in the population at large. Direct effectiveness measures 
of the bivalent vaccine from observational studies are becoming 
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available in the Netherlands [11, 12], as well as other countries 
[13–16]. These studies showed high VE from a 3-dose sched-
ule against the vaccine types, ranging between 73% and 100% 
[12–15]. There are also indications for cross-protection of the 
bivalent vaccine from observational studies; in a recently pub-
lished paper, high VE against HPV-31, HPV-33, and HPV-
45 was observed among women attending their first cervical 
screening in Scotland [15]. However, type-specific estimates of 
VE against hrHPV types other than HPV-16/18/31/33/45 are 
not yet available in a population-based setting.
Knowledge about the cross-protective VE is important to 
understand the overall VE and potential clinical impact of the 
bivalent HPV vaccination program. It is also important for 
vaccine comparisons in health economic assessments [17, 18], 
especially in view of the more recently licensed nonavalent vac-
cine that targets 5 additional hrHPV types associated with about 
19% of all cervical cancer cases (HPV-31, 33, 45, 52, 58) [19]. 
Here, we provide direct VE estimates from the bivalent vaccine 
against hrHPV DNA positivity using cross-sectional data from 
a biennial survey in Dutch sexually transmitted infection (STI) 
clinics (PASSYON study). We present the VE against type-spe-
cific HPV DNA positivity as well as pooled estimates of VE.
METHODS
Study Design and Population
The PASSYON (PApillomavirus Surveillance among STI clinic 
YOungsters in the Netherlands) study is a biennial cross-sec-
tional survey among 16 to 24 years old STI clinic visitors that 
started in 2009, when HPV vaccination was implemented in the 
Netherlands (Figure 1). The study design is described in detail 
elsewhere [20]. Briefly, additional to the routine STI consulta-
tion, participants were asked to provide a self-collected genital 
swab for HPV testing and to fill in a questionnaire including 
self-reported vaccination status. From participants who pro-
vided blood for routine syphilis and HIV testing at the STI 
clinic, serum was collected for HPV serology. Initially, all peo-
ple attending the STI clinic provided blood, but due to policy 
changes from 2013 onwards, only specific groups at high risk for 
syphilis or HIV provided blood. The Medical Ethical Committee 
of the University of Utrecht, the Netherlands approved this study 
(protocol number 08/397). Data was obtained anonymously and 
all participants gave informed consent.
To calculate the VE, we included from the PASSYON study 
years 2011–2015 all women who had been eligible for vaccina-
tion in the Netherlands (ie, women born in 1993 or later [6]), 
who reported their vaccination status and who provided a vag-
inal swab.
Laboratory Methods
Swabs were stored at −20°C until analyses. DNA was extracted 
using the MagnaPure platform (Total Nucleic Acid Isolation Kit, 
Roche, the Netherlands) and eluted in 100-microliter elution buffer. 
HPV-DNA was amplified using the SPF10 primer set. Subsequently, 
HPV-specific amplicons were detected using the DNA enzyme-
linked immunoassay (HPV-DEIA, DDL Diagnostics Laboratory, 
the Netherlands). Amplicons of positive samples were geno-
typed with the Line probe assay (HPV-LiPA25, DDL Diagnostics 
Laboratory, the Netherlands), which is able to detect the 12 hrHPV 
types 16/18/31/33/35/39/45/51/52/56/58/59 [20].
Serum samples were stored at −80°C until analyses [21]. 
HPV antibodies against L1 virus-like particles for types 16 and 
18 were assessed using a multiplex immunoassay. Cut-off levels 
for seropositivity were 9 Luminex Units (LU)/mL for HPV-16 
and 13 LU/mL for HPV-18 [22].
PASSYON round 2009
Prior to vaccination
PASSYON round 2011
Women born in 1993 or
later: ≤ 18 years
PASSYON round 2013
Women born in 1993 or
later: ≤ 20 years
2009 2010 2011 2012 2013 2014
One-o catch-up campaign 
for women born in 1993-
1996
Start NIP beginning with 
birth cohort 1997
PASSYON round 2015
Women born in 1993 or
later: ≤ 22 years
2015
For the current research question, women who were eligible for vaccination in the catch-up campaign or the National
Immunization Program (NIP) (women born in 1993 or later), were selected from the PASSYON study rounds 2011, 2013, 2015.
Only women with a known vaccination status and genital swab were included. In total 1087 women were included.
n=61 (3.2% of 
round 2011)
n=325 (16% of 
round 2013)
n=701 (35% of 
round 2015)
Figure 1. Human papillomavirus (HPV) vaccination in the Netherlands, the PASSYON study design, and the study population selection.
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Validation of Self-reported Vaccination Status
We used serology to validate the self-reported vaccination status 
among those who provided blood. We compared the HPV-16 
and HPV-18 seropositivity rates and antibody concentrations 
between self-reported vaccinated and unvaccinated women. 
To check the discriminative ability of antibody concentrations 
with respect to self-reported vaccination status, we calculated 
the area under the curve (AUC) of a receiver operating charac-
teristic (ROC).
Statistical Analyses
We checked for differences in potential confounders between vac-
cinated and unvaccinated women using Χ2 tests. We included the 
demographic variables age, ethnicity, and education level. Ethnicity 
was based on (parental) country of birth. A woman was defined 
as native Dutch if both parents were born in the Netherlands [23]. 
Education level was self-reported and categorized as high (school 
of higher general secondary education, pre-university education, 
university of applied sciences and university) and low/middle (all 
other levels of education). We also included the number of sex 
partners in the past 6 months, number of lifetime sex partners, 
age at sexual debut (defined as vaginal or anal intercourse), history 
of STIs, condom use with casual partners in the past 6 months, 
hormonal contraceptives use, and current genital chlamydia or 
gonorrhea infection. Chlamydia and gonorrhea infection were 
diagnosed during the routine STI consultation. The other vari-
ables were self-reported and categorized (Table 1).
Vaginal hrHPV DNA positivity was compared between 
women who reported to be vaccinated at least once and women 
who reported to be unvaccinated. Outcomes were type-spe-
cific hrHPV positivity, the vaccine types HPV-16/18 (pooled), 
the hrHPV types included in the nonavalent vaccine (HPV-
16/18/31/33/45/52/58, pooled), and all hrHPV types (HPV-
16/18/31/33/35/39/45/51/52/56/58/59, pooled). We used odds 
ratios (ORs) to estimate the VE, which is suggested to be a suit-
able measure for the relative reduction in HPV positivity (the 
combination of incidence and duration of an HPV infection) 
from cross-sectional data [24]. Because we were interested 
in the VE on an individual level to give the best approxima-
tion of the trial efficacy estimates, we calculated the ORs using 
a logistic mixed model, incorporating all hrHPV types and a 
random intercept to account for residual dependence between 
type-specific infections within individuals. This is an efficient 
method compared to standard logistic regression, because the 
covariates’ coefficients are estimated from all HPV types simul-
taneously and the measurement of VE against multiple HPV 
types (pooled outcomes) is specified as a weighted average [25]. 
All analyses were adjusted for the variables that were associated 
with vaccination status (P < .1). VE was calculated as 1 minus 
the adjusted OR times 100% [26].
Because vaccine efficacy is reduced when recipients are HPV 
positive at vaccination [5, 27], we calculated the VE against the 
pooled outcomes separately among women who were (possi-
bly) sexually active when vaccination was offered and among 
women who were not yet sexually active when vaccination was 
offered. For the catch-up birth cohorts (1993–1996), vaccina-
tion of the first dose was offered on 1 March 2009 and for the 
birth cohorts from 1997 onwards, vaccination of the first dose 
was offered on 1 March in the year they turned 13 [28]. We com-
pared the self-reported age of sexual debut with the age when 
vaccination was offered, and categorized women into either not 
sexually active if the age when vaccination was offered preceded 
sexual debut, or (possibly) sexually active otherwise (including 
women who reported the same age of sexual debut as the age 
when vaccination was offered). Moreover, as cross-protection 
has been suggested to wane over time [29], we calculated the 
VE against the pooled outcomes separately among women who 
were offered vaccination <5 years ago and among women who 
were offered vaccination 5/6 years ago. This categorization was 
chosen to have more or less equal numbers in each subgroup. 
The stratified analyses were adjusted for the variables that were 
associated with vaccination status (P < .1) as well as the age at 
which the women were offered vaccination.
All analyses were performed using SAS version 9.4 (SAS 
Institute Inc., Cary, NC), using proc glimmix with adaptive 
Gauss-Hermite quadrature approximation of the maximum 
likelihood. We used a significance level of P < .05. The records 
with missing data were excluded from the analyses, as these rep-
resented less than 5% of the study population.
Sensitivity Analyses
In sensitivity analyses, we calculated the type-specific and 
pooled estimates of VE for women who reported to be vacci-
nated with 3 doses. Moreover, we repeated the stratified anal-
yses, assuming catch-up cohorts were offered vaccination 
3 months later, on 31 May 2009 because there was variation in 
the dates that vaccination was offered during the catch-up cam-
paign [28].
RESULTS
Study Population
In the PASSYON study years 2011–2015, 1198 women had been 
eligible for HPV vaccination, of which 1087 women reported 
their vaccination status and provided a vaginal swab (Figure 1). 
Of these 1087 women, 649 (60%) reported to be vaccinated at 
least once and 438 (40%) reported to be unvaccinated. Of the 
women who reported to be vaccinated, 70% (n = 456) reported 
to be vaccinated with 3 doses, 11% (n = 72) reported less than 
3 doses, and 19% (n = 121) reported to not know the number 
of doses. Of the women who reported to be vaccinated, 94% 
belonged to the catch-up cohorts (birth cohort 1993–1996).
The characteristics of the study population, stratified by vac-
cination status, are presented in Table  1. Vaccinated women 
were more often native Dutch and highly educated. They had 
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more partners in the past 6 months, were older at sexual debut, 
reported less often a history of STIs, and used hormonal contra-
ceptives more often.
Validation of Self-reported Vaccination Status
In total, 43% of the study population had serum available for 
antibody testing. Of the self-reported vaccinated women, 
96% were seropositive for both HPV-16 and HPV-18. Only 
11 self-reported vaccinated women (4.2%) were seronegative 
for HPV-16 or HPV-18 or both (Supplementary Figure 1). Of 
these 11 women, 8 reported 3 doses, 2 less than 3 doses, and 1 
reported not to know the number of doses. The HPV-16 and 
HPV-18 antibody concentrations agreed well with the self-re-
ported vaccination status (AUC 92.3%).
HPV Prevalence
Overall, 53% tested positive for at least 1 hrHPV type. Of the 
vaccinated women, 49% were positive for an hrHPV type com-
pared to 59% of the unvaccinated women. HPV-51 was the most 
prevalent type followed by HPV-52. For most hrHPV types, the 
Table 1. Characteristics of the Study Population and a Comparison Between Vaccinated and Unvaccinated Women
Total Unvaccinated Vaccinated (≥1 dose)
n (%) n (%) n (%) P valuea
Total 1087 438 649
Age .50
 16–18 years 325 (29.9) 136 (31.1) 189 (29.1)
 19–22 years 762 (70.1) 302 (68.9) 460 (70.9)
Ethnicity <.01
 Native Dutch 854 (78.9) 311 (71.3) 543 (83.9)
 Not native Dutch 229 (21.1) 125 (28.7) 104 (16.1)
Education levelb <.01
 Low/middle 344 (31.7) 171 (39.0) 173 (26.7)
 High 742 (68.3) 267 (61.0) 475 (73.3)
Recent sex partnersc .02
 0–1 partner 310 (28.5) 145 (33.1) 165 (25.4)
 2–3 partners 538 (49.5) 206 (47.0) 332 (51.2)
 ≥4 partners 239 (22.0) 87 (19.9) 152 (23.4)
Lifetime sex partners .24
 0–3 partners 288 (26.9) 127 (29.5) 161 (25.1)
 4–6 partners 346 (32.3) 137 (31.9) 209 (32.6)
 ≥7 partners 438 (40.9) 166 (38.6) 272 (42.4)
Age sexual debutd .06
 ≤14 years 192 (17.8) 91 (21.0) 101 (15.7)
 15–16 years 558 (51.8) 221 (51.0) 337 (52.3)
≥17 years 327 (30.4) 121 (27.9) 206 (32.0)
History of sexually transmitted infections .03
 No 575 (53.1) 213 (48.9) 362 (56.0)
 Yes 241 (22.3) 113 (25.9) 128 (19.8)
 Never tested 267 (24.7) 110 (25.2) 157 (24.3)
Current genital chlamydia/gonorrhea .90
 No 889 (82.1) 357 (82.3) 532 (82.0)
 Yes 194 (17.9) 77 (17.7) 117 (18.0)
Condom use with casual partnersc .32
 (Usually) not 510 (47.0) 199 (45.5) 311 (48.1)
 (Usually) yes 336 (31.0) 132 (30.2) 204 (31.5)
 No casual partners 238 (22.0) 106 (24.3) 132 (20.4)
Ever used hormonal contraceptives <.01
 No 43 (4.0) 26 (6.0) 17 (2.6)
 Yes 1029 (96.0) 404 (94.0) 625 (97.4)
aComparing women vaccinated at least once with unvaccinated women.
bHigh educational level included school of higher general secondary education, pre-university education, university of applied sciences and university, low/middle educational level included 
all other levels of education.
cIn the past 6 months.
dVaginal or anal intercourse.
Numbers do not always add up to 100% because of missing values.
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prevalence was lower for vaccinated compared to unvaccinated 
women (Figure 2).
Vaccine Effectiveness Estimates
Figure 3 presents the adjusted VE against type-specific hrHPV 
DNA positivity and against the pooled estimates. The pooled 
VE against the 2 vaccine types was 89.9%; 92.3% against HPV-
16 and 85.5% against HPV-18. Moreover, we calculated sig-
nificant VE against the nonvaccine types HPV-45, HPV-35, 
HPV-31, and HPV-52. Although borderline nonsignificant, 
the VE against HPV-59 was negative (−89%). The pooled VE 
against the hrHPV types included in the nonavalent vaccine 
was 60.5% and against all 12 hrHPV types 32.9%.
Results from the stratified analyses are presented in Table 2. 
Among women who were not sexually active when vaccination 
was offered, the adjusted pooled VE against the vaccine types 
(92.2%) was higher than among women who were (possibly) 
sexually active when vaccination was offered (81.1%). Among 
women who were offered vaccination 5/6 years ago, we observed 
similar or higher VE against HPV-16/18 (92.4%), the hrHPV 
types included in the nonavalent vaccine (65.5%) and all hrHPV 
types (34.6%) compared to women who were offered vaccination 
<5 years ago (83.2%, 50.7%, and 33.0%, respectively).
Sensitivity Analyses
The VE estimates according to vaccination with 3 doses are pre-
sented in Supplementary Figure 2. Overall, results were compa-
rable to the main analysis. The pooled VE against the vaccine 
types was somewhat higher; 94.7%. The negative VE against 
HPV-59 became borderline statistically significant (−107.2%, 
95% confidence interval [CI] −307.1 to −5.4). Assuming 
vaccination for the catch-up cohorts was offered 3  months 
later did not lead to different results in the stratified analyses 
(Supplementary Table 1).
DISCUSSION
 We demonstrated high VE from the bivalent vaccine against 
the vaccine types HPV-16/18 and significant cross-protection 
against the hrHPV types 45, 35, 31, and 52. Together, these 
cross-protective types are associated with approximately an 
additional 15% of all cervical cancers [3]. To our knowledge, 
this is the first observational study reporting VE against hrHPV 
positivity on a type-specific level for the bivalent vaccine. The 
cross-protective VE from the bivalent vaccine suggests that 
the impact of HPV vaccination will be greater than anticipated 
upon introduction [30].
The high HPV prevalence among STI clinic visitors and 
sensitive diagnostics to measure infection status, enabled us 
to measure the type-specific VE against HPV positivity from 
cross-sectional data. The usefulness of using data from high-
risk populations to infer VE in an early stage after the introduc-
tion of mass vaccination has been shown by Australian studies; 
2  years after HPV vaccination was implemented in Australia, 
a decline was observed in genital warts among young women 
and heterosexual men visiting sexual health services [31]. This 
declining trend was later confirmed in other settings more rep-
resentative for the general population [32, 33].
We do acknowledge some limitations. First, we used self-re-
ported vaccination status, which is prone to recall bias. The 
vaccination coverage in our study population was comparable 
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Figure 2. High-risk human papillomavirus (HPV) prevalence by vaccination status.
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to the vaccination coverage in the total Dutch population: 52% 
of the catch-up cohorts received 3 doses and this increased to 
59% for birth cohort 1999; an additional 3.8% received less than 
3 doses [34–36]. We showed reliable reporting of vaccination 
status in our study, but we could only validate self-reported 
vaccination status among women with serum available. Due to 
the recent policy changes for syphilis and HIV testing at the STI 
clinic towards high-risk individuals, women with serum availa-
ble could be biased towards having higher antibody concentra-
tions [37], complicating the distinction between vaccinated and 
unvaccinated women. Nevertheless, antibody concentrations 
performed well in discriminating self-reported vaccination sta-
tus. Moreover, misclassification according to self-reported vacci-
nation status would lead to conservative estimates of VE. Second, 
because our study population consisted mainly of women who 
were vaccinated during the catch-up campaign, some women 
were probably HPV infected at vaccination, leading to lower 
VE compared to an HPV-naive population [5, 27]. Indeed, we 
showed a higher VE against the vaccine types among women 
with a reported sexual debut after vaccination was offered, in 
line with results from the vaccine trials. Last, most women in our 
study were vaccinated according to the 3-dose schedule as this 
was the guideline prevailing at the time of vaccination, so our 
results might not be generalizable to the current 2-dose sched-
ule. In our study, the VE against the vaccine types was higher for 
3 doses compared to at least 1 dose, indicating a lower VE among 
women who did not know the number of doses or who reported 
less than 3 doses. Because of a limited number of women who 
reported having received 2 doses and because we did not known 
the interval between doses, we were unable to evaluate the cur-
rent 2-dose schedule with 6 months between doses.
Our results agree well with the literature. Overall, the VE 
that we calculated against HPV-16/18 positivity and against 
cross-protective types, are in line with data from the bivalent 
vaccine trials [7]. In the PATRICIA trial, the largest phase III 
trial, cross-protection has been described against persistent 
HPV-31, 33, 45, 51, and 52 infections and against incident 
HPV-35 infection [8, 9]. In contrast to the PATRICIA trial, we 
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A
Figure 3. Vaccine effectiveness (VE) for at least one dose against, (A) type-specific high-risk (hr) human papillomavirus (HPV) positivity and (B) pooled estimates. The hr 
nonavalent HPV types included: HPV-16/18/31/33/45/52/58. All hrHPV types included: HPV-16/18/31/33/35/39/45/51/52/56/58/59. VE was corrected for: ethnicity, educa-
tion level, recent sex partners, age at sexual debut, history of sexually transmitted infections, and hormonal contraceptives use.
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did not find statistically significant cross-protection against 
HPV-33 or HPV-51. In the Costa Rica Vaccine Trial, the effi-
cacy against HPV-33 was, like ours, not statistically significant 
(32%, 95% CI −41 to 68, against 6-month persistent infection) 
and against HPV-51 negative (−56%, 95% CI −114 to −14, 
against 6-month persistent infection) [10]. We found no effect 
on HPV-51. Effect estimates from observational studies against 
nonvaccine HPV types are still limited. Trend studies found 
that the HPV-31/33/45 prevalence decreased in postvaccina-
tion periods compared to prevaccination periods, suggestive of 
cross-protection [38–40]. Among women who underwent their 
first cervical screening in Scotland, vaccine effectiveness was 
observed against HPV-31, 33, and 45 [15].
In our study, the VE against the pooled outcomes was sim-
ilar or even higher among women who were offered vaccination 
5 or 6 years ago compared to women who were offered vacci-
nation more recently. These analyses were adjusted for sexual 
behavior and age when vaccination was offered. These findings 
are in line with those from Scotland, where high VE against the 
vaccine types HPV-16/18 and against HPV types 31, 33, and 45 
was observed up to 7 years after vaccination [15]. Due to low 
numbers in the stratified analyses, we were unable to calculate 
the type-specific VE by time since vaccination was offered. As 
the PASSYON study continues, we will repeat the analyses to 
investigate the duration of protection further.
We observed a negative VE against HPV-59, which was just 
statistically significant in sensitivity analysis restricted to women 
who reported 3 doses versus no vaccination. The SPF10-LiPA25 
assay that we used in the current study is very sensitive, but the 
detection limit for HPV-59 is much higher than for the other 
hrHPV types, which could lead to an underestimation of the 
HPV-59 prevalence [41, 42]. Moreover, this assay is a broad-spec-
trum polymerase chain reaction (PCR) in which some competi-
tion between types in the same sample can occur [43]. Possibly 
due to the reduced occurrence of vaccine and cross-protection 
types, HPV-59 was more often detected in vaccinated compared 
to unvaccinated women, which would lead to an artificial nega-
tive VE. This phenomenon of increased detection is referred to as 
unmasking [44]. Another possible explanation for a negative VE 
is type replacement. This means that an HPV type is taking over 
the vacated ecological niche of the vaccine and cross-protective 
types [44]. In post hoc analyses of the PATRICIA trial, an alterna-
tive HPV DNA testing algorithm was used including a type-spe-
cific test that is not affected by competition between types. Using 
this type-specific test next to the SPF10-LiPA25, the number of 
HPV-59 cases roughly doubled, but the vaccine efficacy against 
HPV-59 remained (nonsignificantly) negative for 12-month 
persistent infection (−29.2%) [9]. Because the sensitivity of the 
SPF10-LiPA25 for HPV-59 is limited and because the confidence 
intervals were large, the negative VE against HPV-59 in our study 
should be interpreted with caution. Further research is necessary 
to investigate what is causing this negative VE estimate.
To conclude, we showed high VE of the bivalent vaccine 
against HPV-16/18 positivity and significant cross-protection 
against HPV-45, HPV-35, HPV-31, and HPV-52 in a Dutch 
high-risk population. We observed cross-protection against 3 
of the 5 additional hrHPV types included in the nonavalent vac-
cine. As the cross-protective types HPV-45, HPV-35, HPV-31, 
Table 2. Vaccine Effectiveness Against Pooled Estimates, Stratified by Sexual Activity When Vaccination Was Offered and Time Since Vaccination Was 
Offered
VE (95%CI)a
n (%) HPV-16/18 Hr nonavalent typesb All hrHPVc
Women not sexually active when vaccination was offered
Unvaccinated 303 (37.7)
Vaccinated (≥1 dose) 501 (62.3) 92.2 (83.2–96.4) 60.1 (47.1–70.0) 29.6 (13.4–42.7)
Women (possibly) sexually active when vaccination was offeredd
Unvaccinated 119 (47.6)
Vaccinated (≥1 dose) 131 (52.4) 81.1 (52.1–92.5) 60.2 (36.2–75.2) 39.9 (16.3–56.8)
Women offered vaccination <5 years ago
Unvaccinated 178 (43.1)
Vaccinated (≥1 dose) 235 (56.9) 83.2 (57.9–93.3) 50.7 (23.9–68.1) 33.0 (10.4–49.8)
Women offered vaccination 5/6 years ago
Unvaccinated 244 (38.1)
Vaccinated (≥1 dose) 397 (61.9) 92.4 (83.6–96.5) 65.5 (53.9–74.1) 34.6 (19.0–47.2)
Abbreviations: CI, confidence interval; HPV, human papillomavirus; hr, high-risk; VE, vaccine effectiveness.
aVE was corrected for: ethnicity, education level, recent sex partners, age at sexual debut, history of sexually transmitted infections, hormonal contraceptives use, and age vaccination was 
offered.
bIncluding HPV types HPV-16/18/31/33/45/52/58.
cIncluding HPV types HPV-16/18/31/33/35/39/45/51/52/56/58/59.
dIncludes women who reported the same age (in years) of sexual debut as the age they were offered vaccination.
For the catch-up cohorts, vaccination was offered on 1 March 2009. For the cohorts vaccinated in the National Immunization Program, vaccination was offered on 1 March in the year they 
turned 13 years old.
Downloaded from https://academic.oup.com/jid/article-abstract/217/2/213/4617853
by Erasmus University Rotterdam user
on 09 April 2018
220 • JID 2018:217 (15 January) • Woestenberg et al
and HPV-52 are associated with an additional 15% of all cer-
vical cancer cases, cross-protection of the bivalent vaccine can 
have a major impact on cancer prevention.
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Diseases online. Consisting of data provided by the authors to 
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